FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes von de Poel, E., Spelier, S., Hagemeijer, M.C., van Mourik, P., Suen, S.W.F., Vonk, A.M., Brunsveld, J.E., Ithakisiou, G.N., Kruisselbrink, E., Oppelaar, H., Berkers, G., de Winter de Groot, K.M., Heida-Michel, S., Jans, S.R., van Panhuis, H., Bakker, M., van der Meer, R., Roukema, J., Dompeling, E., Weersink, E.J.M., Koppelman, G.H., Blaazer, A.R., Muijlwijk-Koezen, J.E., van der Ent, C.K., Beekman, J.M.

Volltext